Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial

被引：0

作者：

Lipton, R. ^{[1
]}

Chalermpalanupap, N. ^{[2
]}

Nahas-Geiger, S. ^{[3
]}

Pozo-Rosich, P. ^{[4
]}

McAllister, P. ^{[5
]}

Tatsuoka, Y. ^{[6
]}

Liu, Y. ^{[7
]}

Dabruzzo, B. ^{[2
]}

Smith, J. ^{[7
]}

Bilchik, T. ^{[8
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY USA

[2] AbbVie, Madison, NJ USA

[3] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA

[4] Univ Calif Los Angeles, Los Angeles, CA USA

[5] New England Inst Neurol & Headache, Stamford, CT USA

[6] Tatsuoka Neurol Clin, Kyoto, Japan

[7] AbbVie, N Chicago, IL USA

[8] Yale Sch Med, New Haven, CT USA

来源：

HEADACHE | 2023年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-180

引用

页码：168 / 169

页数：2

共 50 条

[41] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study [J].

Rothrock, J. F. ;

Luo, L. ;

Eross, E. J. ;

Sommer, K. ;

Blumenfeld, A. M. .

HEADACHE, 2020, 60 :93-93

[42] Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials [J].

Schim, Jack D. ;

Anderson, Carlton ;

Brunner, Elizabeth ;

Hirman, Joe ;

Ogbru, Annette ;

Cady, Roger ;

McGill, Lora .

HEADACHE, 2022, 62 (05) :558-565

[43] Baseline Predictors of Clinical Response: A Post Hoc Analysis of the Ambition Trial [J].

Benza, Raymond ;

Blair, Christiana ;

Patel, Krishna ;

Eads, Michael .

CHEST, 2017, 152 (04) :1052A-1052A

[44] Intravenous Fluids for Acute Migraine. a Post-hoc Analysis of Clinical Trial Data [J].

Friedman, B. ;

Balbin, J. .

HEADACHE, 2015, 55 :138-138

[45] Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis [J].

Shigekazu Kitamura ;

Takao Takeshima ;

Daishi Yui ;

Gabriel Paiva da Silva Lima ;

Reija Koukakis ;

Cheng Peng ;

Ryuji Yoshida ;

Yotaro Numachi ;

Miki Hasebe .

Neurology and Therapy, 2023, 12 (6) :1993-2006

[46] Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study [J].

Wang, Shuu-Jiun ;

Kim, Byung-Kun ;

Wang, Hebo ;

Zhou, Jiying ;

Wan, Qi ;

Yu, Tingmin ;

Lian, Yajun ;

Arkuszewski, Michal ;

Ecochard, Laurent ;

Snellman, Josefin ;

Wen, Shihua ;

Yin, Fangfang ;

Li, Zheng ;

Su, Wendy ;

Yu, Shengyuan .

HEADACHE, 2025, 65 (01) :143-152

[47] Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis [J].

Kitamura, Shigekazu ;

Takeshima, Takao ;

Yui, Daishi ;

Lima, Gabriel Paiva da Silva ;

Koukakis, Reija ;

Peng, Cheng ;

Yoshida, Ryuji ;

Numachi, Yotaro ;

Hasebe, Miki .

NEUROLOGY AND THERAPY, 2023, 12 (06) :1993-2006

[48] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial [J].

Dodick, David W. ;

Ailani, Jessica ;

Goadsby, Peter J. ;

Trugman, Joel M. ;

Finnegan, Michelle ;

Lakkis, Hassan ;

Li, Ye ;

Szegedi, Armin .

CEPHALALGIA, 2019, 39 :183-184

[49] Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial [J].

Kivitz, Alan ;

Sedova, Liliana ;

Churchill, Melvin ;

Vizcaya, Cynthia ;

Sutariya, Reema ;

Cao, Wenhao ;

Singhal, Atul .

ARTHRITIS & RHEUMATOLOGY, 2024, 76 :4750-4752

[50] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial [J].

Dodick, D. W. ;

Ailani, J. ;

Goadsby, P. J. ;

Trugman, J. M. ;

Finnegan, M. ;

Lakkis, H. ;

Li, Y. ;

Szegedi, A. .

HEADACHE, 2019, 59 :79-80

← 1 2 3 4 5 →